MX2009013948A - Derivados de 6-cicloamino-3-(piridin-4-il)imidazo[1,2-b] piridazina, su preparacion y uso terapéutico. - Google Patents
Derivados de 6-cicloamino-3-(piridin-4-il)imidazo[1,2-b] piridazina, su preparacion y uso terapéutico.Info
- Publication number
- MX2009013948A MX2009013948A MX2009013948A MX2009013948A MX2009013948A MX 2009013948 A MX2009013948 A MX 2009013948A MX 2009013948 A MX2009013948 A MX 2009013948A MX 2009013948 A MX2009013948 A MX 2009013948A MX 2009013948 A MX2009013948 A MX 2009013948A
- Authority
- MX
- Mexico
- Prior art keywords
- group
- groups
- optionally substituted
- cycloamino
- imidazo
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 title abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 abstract 1
- 125000002733 (C1-C6) fluoroalkyl group Chemical group 0.000 abstract 1
- -1 -NR4R5 Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004428 fluoroalkoxy group Chemical group 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Addiction (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
La presente invención se refiere a derivados de 6-cicloamino-3-(piridin-4-il)imidazo[1,2-b]piridazina que corresponden a la fórmula general de (I), en el cual cuya fórmula (I) R2 es un grupo arilo opcionalmente substituido por uno o más substituyentes seleccionados de los átomos de halógeno, y C1-6 alquilo, C1-6 alquiloxi, C1-6 alquiltio, C1-6 fluoroalquilo, C1-6 fluoroalquiloxi y grupos -CN; R3 es un átomo de hidrógeno o un C1-3 alquilo, -NR4R5, hidroxilo o un grupo C1-4 alquiloxi; -A es un grupo C1-7 alquileno opcionalmente substituido por uno o dos grupos Ra; B es un grupo C1-7 alquileno opcionalmente substituido por un grupo Ra; L es cualquiera de un átomo de nitrógeno opcionalmente substituido por un grupo R, o Ra o un átomo de carbono substituido por un grupo R y un grupo Ra o dos grupos Re2; los átomos de carbono de A y de B o de los grupos Re2 son opcionalmente substituidos por uno o más grupos Rf los cuales pueden ser idénticos o diferentes entre ellos; R7 y Ra son, independientemente entre ellos, un átomo de hidrógeno o un grupo C1-6-alquilo. Método de preparación y uso terapéutico.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94678507P | 2007-06-28 | 2007-06-28 | |
| FR0704661A FR2918061B1 (fr) | 2007-06-28 | 2007-06-28 | Derives de 6-cycloamino-3-(pyridin-4-yl)imidazo°1,2-b!- pyridazine,leur preparation et leur application en therapeutique. |
| PCT/FR2008/000902 WO2009016286A2 (fr) | 2007-06-28 | 2008-06-26 | Derives de 6-cycloamino-3-(pyridin-4-yl)imidazo[1, 2-b]-pyridazine, leur preparation et leur application en therapeutique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2009013948A true MX2009013948A (es) | 2010-03-09 |
Family
ID=39203151
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2009013948A MX2009013948A (es) | 2007-06-28 | 2008-06-26 | Derivados de 6-cicloamino-3-(piridin-4-il)imidazo[1,2-b] piridazina, su preparacion y uso terapéutico. |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US8354405B2 (es) |
| EP (1) | EP2170889B1 (es) |
| JP (1) | JP5537424B2 (es) |
| KR (1) | KR20100050492A (es) |
| CN (1) | CN101765602A (es) |
| AR (1) | AR069269A1 (es) |
| AU (1) | AU2008281662A1 (es) |
| BR (1) | BRPI0814807A2 (es) |
| CA (1) | CA2691866A1 (es) |
| CL (1) | CL2008001932A1 (es) |
| CO (1) | CO6251269A2 (es) |
| EA (1) | EA201070072A1 (es) |
| FR (1) | FR2918061B1 (es) |
| MA (1) | MA31572B1 (es) |
| MX (1) | MX2009013948A (es) |
| NZ (1) | NZ582677A (es) |
| PA (1) | PA8786101A1 (es) |
| PE (1) | PE20090556A1 (es) |
| TW (1) | TW200911812A (es) |
| UY (1) | UY31193A1 (es) |
| WO (1) | WO2009016286A2 (es) |
| ZA (1) | ZA200909186B (es) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7868001B2 (en) * | 2007-11-02 | 2011-01-11 | Hutchison Medipharma Enterprises Limited | Cytokine inhibitors |
| EP2300469B1 (en) | 2008-05-13 | 2015-06-24 | Novartis AG | Fused nitrogen containing heterocycles and compositions thereof as kinase inhibitors |
| FR2934994B1 (fr) * | 2008-08-12 | 2010-09-17 | Sanofi Aventis | Derives de 2-alkyl-6cycloamino-3-(pyridin-4-yl)imidaz°1,2-b! pyridazine, leur preparation et leur application en therapeutique |
| FR2939134A1 (fr) * | 2008-12-01 | 2010-06-04 | Sanofi Aventis | Derives de 6-cycloamino-3-(1h-pyrrolo°2,3-b!pyridin-4-yl) imidazo°1,2-b!-pyridazine, leur preparation et leur application en therapeutique |
| FR2940284B1 (fr) * | 2008-12-19 | 2011-02-18 | Sanofi Aventis | Derives de 6-cycloamino-2,3-di-pyridinyl-imidazo°1,2-b!- pyridazine,leur preparation et leur application en therapeutique |
| FR2940285A1 (fr) * | 2008-12-19 | 2010-06-25 | Sanofi Aventis | Derives de 6-cycloamino-2-thienyl-3-(pyridin-4-yl)imidazo °1,2-b!-pyridazine et 6-cycloamino-2-furanyl-3- (pyridin-4-yl)imidazo°1,2-b!-pyridazine, leur preparation et leur application en therapeutique |
| US8680275B2 (en) | 2009-10-23 | 2014-03-25 | Janssen Pharmaceutica Nv | Fused heterocyclic compounds as orexin receptor modulators |
| US9062044B2 (en) | 2009-10-23 | 2015-06-23 | Janssen Pharmaceutica Nv | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators |
| US8653263B2 (en) * | 2009-10-23 | 2014-02-18 | Janssen Pharmaceutica | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators |
| EA020847B1 (ru) | 2009-10-30 | 2015-02-27 | Янссен Фармацевтика Нв | ПРОИЗВОДНЫЕ ИМИДАЗО[1,2-b]ПИРИДАЗИНА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ PDE10 |
| AR080754A1 (es) | 2010-03-09 | 2012-05-09 | Janssen Pharmaceutica Nv | Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10 |
| US9801853B2 (en) | 2010-04-06 | 2017-10-31 | Fred Hutchinson Cancer Research Center | Methods for identifying and using inhibitors of casein kinase 1 epsilon isoform for inhibiting the growth and/or proliferation of MYC-driven tumor cells |
| UY33597A (es) | 2010-09-09 | 2012-04-30 | Irm Llc | Compuestos y composiciones como inhibidores de la trk |
| ES2650744T3 (es) | 2010-12-14 | 2018-01-22 | Electrophoretics Limited | Inhibidores de la caseína quinasa 1 delta (CK1delta) |
| TWI617559B (zh) * | 2010-12-22 | 2018-03-11 | 江蘇恆瑞醫藥股份有限公司 | 2-芳基咪唑并[1,2-b]嗒.2-苯基咪唑并[1,2-a]吡啶,和2-苯基咪唑并[1,2-a]吡衍生物 |
| WO2012145581A1 (en) | 2011-04-20 | 2012-10-26 | Janssen Pharmaceutica Nv | Disubstituted octahy-dropyrrolo [3,4-c] pyrroles as orexin receptor modulators |
| WO2013000924A1 (en) | 2011-06-27 | 2013-01-03 | Janssen Pharmaceutica Nv | 1-ARYL-4-METHYL-[1,2,4]TRIAZOLO[4,3-a]QUINOXALINE DERIVATIVES |
| WO2013023084A2 (en) | 2011-08-09 | 2013-02-14 | Fred Hutchinson Cancer Research Center | Methods and compositions for inhibiting the growth and/or proliferation of myc-driven tumor cells |
| EP2863909B1 (en) | 2012-06-26 | 2020-11-04 | Janssen Pharmaceutica N.V. | Combinations comprising 4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline compounds as pde 2 inhibitors and pde 10 inhibitors for use in the treatment of neurological or metabolic disorders |
| JP6272846B2 (ja) | 2012-06-27 | 2018-01-31 | 4エスツェー ディスカバリー ゲゼルシャフト ミット ベシュレンクテル ハフツング | 癌、自己免疫性炎症及びcns疾患の処置のためのビフルオロジオキサラン−アミノ−ベンゾイミダゾールキナーゼ阻害剤 |
| MX362197B (es) | 2012-07-09 | 2019-01-08 | Janssen Pharmaceutica Nv | Derivados de imidazo[1,2-b]piridazina e imidazo[1,2-a]pirazina como inhibidores de la fosfodiesterasa 10; y el uso de los mismos en el tratamiento de trastornos neurológicos, psiquiátricos y metabólicos. |
| CZ2012538A3 (cs) * | 2012-08-08 | 2014-02-19 | Masarykova Univerzita | Inhibitory pro léčbu B-buněčné chronické lymfocytární leukémie |
| US10676746B2 (en) | 2013-11-22 | 2020-06-09 | Fred Hutchinson Cancer Research Center | Methods for identifying therapeutic targets and treating monitoring cancers |
| ES2728932T3 (es) * | 2014-01-09 | 2019-10-29 | Intra Cellular Therapies Inc | Compuestos orgánicos |
| WO2015114638A2 (en) | 2014-02-03 | 2015-08-06 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Method of eliminating stem cells |
| BR112018067906A2 (pt) | 2016-03-10 | 2019-01-29 | Janssen Pharmaceutica Nv | métodos de tratamento de depressão usando antagonistas do receptor de orexina-2 |
| US11028091B2 (en) * | 2017-03-14 | 2021-06-08 | Daiichi Sankyo Company, Limited | Method for producing 3, 6-disubstituted imidazo[1, 2-b]pyridazine derivative |
| JP6594570B2 (ja) | 2017-03-20 | 2019-10-23 | フォーマ セラピューティクス,インコーポレイテッド | ピルビン酸キナーゼ(pkr)活性化剤としてのピロロピロール組成物 |
| US10973820B2 (en) | 2017-12-13 | 2021-04-13 | Facio Intellectual Property B.V. | Compounds for treatment of diseases related to DUX4 expression |
| WO2020061255A1 (en) | 2018-09-19 | 2020-03-26 | Forma Therapeutics, Inc. | Activating pyruvate kinase r |
| WO2020061378A1 (en) | 2018-09-19 | 2020-03-26 | Forma Therapeutics, Inc. | Treating sickle cell disease with a pyruvate kinase r activating compound |
| CN111471056B (zh) * | 2019-01-23 | 2021-07-02 | 成都先导药物开发股份有限公司 | 一种大环类免疫调节剂 |
| TW202112368A (zh) * | 2019-06-13 | 2021-04-01 | 荷蘭商法西歐知識產權股份有限公司 | 用於治療有關dux4表現之疾病的抑制劑組合 |
| AU2020350763A1 (en) | 2019-09-19 | 2022-04-07 | Novo Nordisk Health Care Ag | Pyruvate kinase R (PKR) activating compositions |
| WO2021105481A1 (en) * | 2019-11-29 | 2021-06-03 | Facio Intellectual Property B.V. | Novel compounds for treatment of diseases related to dux4 expression |
| US11193891B2 (en) | 2019-12-20 | 2021-12-07 | Robert Bosch Gmbh | Receptors and spacers for a fluorescence-based lead ion chemosensor |
| CN115298183A (zh) * | 2020-03-27 | 2022-11-04 | 北京原基华毅生物科技有限公司 | 作为酪蛋白激酶抑制剂的化合物 |
| WO2021190616A1 (en) * | 2020-03-27 | 2021-09-30 | Gritscience Biopharmaceuticals Co., Ltd. | Methods for inhibiting casein kinases |
| GB202019622D0 (en) * | 2020-12-11 | 2021-01-27 | Adorx Therapeutics Ltd | Antagonist compounds |
| US12128035B2 (en) | 2021-03-19 | 2024-10-29 | Novo Nordisk Health Care Ag | Activating pyruvate kinase R |
| PE20242113A1 (es) | 2021-10-14 | 2024-10-28 | Incyte Corp | Compuestos de quinolina como inhibidores de kras |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0103926D0 (en) * | 2001-02-17 | 2001-04-04 | Astrazeneca Ab | Chemical compounds |
| EP1388541A1 (en) * | 2002-08-09 | 2004-02-11 | Centre National De La Recherche Scientifique (Cnrs) | Pyrrolopyrazines as kinase inhibitors |
| AU2004303826A1 (en) * | 2003-12-11 | 2005-07-07 | Aventis Pharmaceuticals Inc. | Substituted 1H-pyrrolo[3,2-b, 3,2-c, and 2,3-c]pyridine-2-carboxamides and related analogs as inhibitors of casein kinase I Epsilon |
| US7718801B2 (en) * | 2004-08-31 | 2010-05-18 | Banyu Pharmaceutical Co., Ltd. | Substituted imidazole derivative |
| WO2006070943A1 (ja) * | 2004-12-28 | 2006-07-06 | Takeda Pharmaceutical Company Limited | 縮合イミダゾール化合物およびその用途 |
| US20100216798A1 (en) * | 2005-07-29 | 2010-08-26 | Astellas Pharma Inc | Fused heterocycles as lck inhibitors |
| EP1845098A1 (en) * | 2006-03-29 | 2007-10-17 | Ferrer Internacional, S.A. | Imidazo[1,2-b]pyridazines, their processes of preparation and their use as GABA receptor ligands |
| CN101600718B (zh) * | 2006-11-06 | 2013-07-03 | 特雷罗药物股份有限公司 | 咪唑并[1,2-b]哒嗪和吡唑并[1,5-a]嘧啶衍生物及其作为蛋白激酶抑制剂的用途 |
| AR064420A1 (es) * | 2006-12-21 | 2009-04-01 | Alcon Mfg Ltd | Composiciones farmaceuticas oftalmicas que comprenden una cantidad efectiva de analogos de 6-aminoimidazo[1,2b]piridazinas, utiles para el tratamiento del glaucoma y/o controlar la presion intraocular normal o elevada(iop). |
-
2007
- 2007-06-28 FR FR0704661A patent/FR2918061B1/fr active Active
-
2008
- 2008-06-25 TW TW097123772A patent/TW200911812A/zh unknown
- 2008-06-26 MX MX2009013948A patent/MX2009013948A/es unknown
- 2008-06-26 CA CA002691866A patent/CA2691866A1/fr not_active Abandoned
- 2008-06-26 WO PCT/FR2008/000902 patent/WO2009016286A2/fr not_active Ceased
- 2008-06-26 EA EA201070072A patent/EA201070072A1/ru unknown
- 2008-06-26 BR BRPI0814807-4A2A patent/BRPI0814807A2/pt not_active IP Right Cessation
- 2008-06-26 NZ NZ582677A patent/NZ582677A/en not_active IP Right Cessation
- 2008-06-26 PE PE2008001090A patent/PE20090556A1/es not_active Application Discontinuation
- 2008-06-26 KR KR1020107001891A patent/KR20100050492A/ko not_active Withdrawn
- 2008-06-26 EP EP08826677.0A patent/EP2170889B1/fr active Active
- 2008-06-26 JP JP2010514033A patent/JP5537424B2/ja not_active Expired - Fee Related
- 2008-06-26 CN CN200880100885A patent/CN101765602A/zh active Pending
- 2008-06-26 AU AU2008281662A patent/AU2008281662A1/en not_active Abandoned
- 2008-06-27 CL CL2008001932A patent/CL2008001932A1/es unknown
- 2008-06-27 UY UY31193A patent/UY31193A1/es not_active Application Discontinuation
- 2008-06-27 PA PA20088786101A patent/PA8786101A1/es unknown
- 2008-06-27 AR ARP080102783A patent/AR069269A1/es unknown
-
2009
- 2009-12-23 ZA ZA2009/09186A patent/ZA200909186B/en unknown
- 2009-12-24 US US12/647,059 patent/US8354405B2/en not_active Expired - Fee Related
- 2009-12-28 CO CO09148262A patent/CO6251269A2/es not_active Application Discontinuation
-
2010
- 2010-01-26 MA MA32556A patent/MA31572B1/fr unknown
-
2012
- 2012-09-14 US US13/617,678 patent/US8846676B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| KR20100050492A (ko) | 2010-05-13 |
| US8354405B2 (en) | 2013-01-15 |
| PE20090556A1 (es) | 2009-06-01 |
| AR069269A1 (es) | 2010-01-13 |
| FR2918061A1 (fr) | 2009-01-02 |
| UY31193A1 (es) | 2009-01-30 |
| US8846676B2 (en) | 2014-09-30 |
| JP5537424B2 (ja) | 2014-07-02 |
| US20100179154A1 (en) | 2010-07-15 |
| CL2008001932A1 (es) | 2009-09-25 |
| TW200911812A (en) | 2009-03-16 |
| CA2691866A1 (fr) | 2009-02-05 |
| AU2008281662A1 (en) | 2009-02-05 |
| NZ582677A (en) | 2011-12-22 |
| EA201070072A1 (ru) | 2010-08-30 |
| US20130012516A1 (en) | 2013-01-10 |
| ZA200909186B (en) | 2011-02-23 |
| CN101765602A (zh) | 2010-06-30 |
| WO2009016286A2 (fr) | 2009-02-05 |
| WO2009016286A3 (fr) | 2009-04-09 |
| MA31572B1 (fr) | 2010-08-02 |
| EP2170889A2 (fr) | 2010-04-07 |
| BRPI0814807A2 (pt) | 2015-02-03 |
| EP2170889B1 (fr) | 2016-08-17 |
| CO6251269A2 (es) | 2011-02-21 |
| FR2918061B1 (fr) | 2010-10-22 |
| JP2010531342A (ja) | 2010-09-24 |
| PA8786101A1 (es) | 2009-01-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2009013948A (es) | Derivados de 6-cicloamino-3-(piridin-4-il)imidazo[1,2-b] piridazina, su preparacion y uso terapéutico. | |
| WO2009144394A8 (fr) | Derives de 2-aryl-6-phenyl-imidazo[1,2-a]pyridines polysubstitues, leur préparation et leur application en thérapeutique | |
| UA95976C2 (en) | 2-ARYL-6-PHENYLIMIDAZO[1,2-b]PYRIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | |
| MX2010003445A (es) | Derivados de nicotinamida, su preparacion y su uso terapeutico. | |
| NZ608718A (en) | Imidazo[1,2-b]pyridazine and imidazo[4,5-b]pyridine derivatives as jak inhibitors | |
| WO2009144395A8 (fr) | DÉRIVÉS POLYSUBSTITUES DE 2-HETEROARYL-6-PHENYL-IMIDAZO[1,2- α]PYRIDINES, LEUR PRÉPARATION ET LEUR APPLICATION EN THÉRAPEUTIQUE | |
| WO2009112678A3 (fr) | Derives de carboxam i d es azabicycliques, leur preparation et leur application en therapeutique. | |
| MA31616B1 (fr) | DERIVES DE 6-CYCLOAMINO-S-(PYRIDAZIN-YL)IMIDAZO[1,2-b]-PYRIDAZINE, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE | |
| EA201071111A1 (ru) | ПОЛИЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ 6-ГЕТЕРОАРИЛИМИДАЗО[1,2-a]ПИРИДИНОВ, ИХ ПОЛУЧЕНИЕ И ИХ ПРИМЕНЕНИЕ В ТЕРАПИИ | |
| TN2012000608A1 (en) | Imidazopyridine derivatives, process for the preparation thereof and therapeutic use thereof | |
| RU2011101140A (ru) | Пирроло[2,3-b]пиридиновые производные в качестве ингибиторов протеинкиназ | |
| NZ586579A (en) | Fused heterocyclic derivatives and methods of use as c-met inhibitors | |
| MX2013005486A (es) | Inhibidores de la replicacion del vih. | |
| TN2009000267A1 (en) | 6-benzyl-2,3,4,7-tetrahydro-indolo [2, 3-c] quinoline compounds useful as pde5 inhibitors | |
| WO2010130934A3 (fr) | Derives de 2-cycloamino-5-(pyridin-4-yl)imidazo[2,1-b][1,3,4]thiadiazole, leur preparation et leur application en therapeutique | |
| MX2013005734A (es) | Derivados de heteroarilsulfonamidas, su preparacion y su aplicacion en terapia humana. | |
| WO2010011546A3 (en) | Pyrrolo [3, 2-b]pyridines and pyrazolo [4, 3 -b] pyridines having 5-ht6 receptor affinity | |
| WO2011161537A3 (en) | 3,4-dihydropyrrolo[1,2-a]pyrazine-2,8(1h)-dicarboxamide derivatives, preparation thereof and therapeutic use thereof | |
| BRPI0922760A2 (pt) | derivados de 6-ciclo amino -3-(1h-pirrolo [2,3-b] piridin -4-il) imidazo [1,2-b]- piridazina, o respectivo preparo e a respectiva aplicação em terapêutica | |
| TW200728303A (en) | N-(arylalkyl)-1H-pyrrolopyridine-2-carboxamide derivatives, preparation thereof and therapeutic use thereof | |
| WO2009106750A3 (fr) | Dérivés 6-heterocyclique-imidazo[1,2-a]pyrroine-2-carboxamides, leur préparation et leur application en thérapeutique | |
| WO2009106752A3 (fr) | Derives de 2-heteroaroyl-imidazol[1,2-a]pyridine, leur preparation et leur application en therapeutique | |
| MX2010007348A (es) | Derivados de n-fenil-imidazo[1,2-a]piridin-2-carboxamidas, su preparacion y su aplicacion terapeutica. | |
| WO2009106751A3 (fr) | Dérivés de n-heterocyclique-6-heterocyclique-imidazo[1,2- a]pyridiνe-2-carb0xamides, leur préparation et leur application en thérapeutique | |
| TW200942538A (en) | 2-benzoylimidazo[1,2-a]pyridine derivatives, preparation thereof and therapeutic use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HH | Correction or change in general |